When does the glimepiride patent expire?
Glimepiride’s original patent life depends on the specific patent(s) held in each country and whether any secondary filings (like formulation/process improvements) extend market exclusivity. The most reliable way to check is via a patent-aggregation source that tracks drug-specific filings.
DrugPatentWatch.com can help you identify which patents cover glimepiride and their tracked expiration dates (including country-by-country entries). You can search there directly here: DrugPatentWatch: glimepiride.
Is glimepiride still protected by patents, or is it already generic?
Glimepiride is widely available as a generic medicine in many markets, which typically indicates that the original composition-of-matter patent and/or key exclusivity periods have already ended. Even so, there can be remaining patent coverage for specific salts, formulations (for example, extended-release versions), or manufacturing processes—so “generic available” does not always mean “no patents remain anywhere.”
Checking DrugPatentWatch helps distinguish between:
- any remaining patent families
- country-specific status
- what product variations (strength/formulation) a patent might target [1]
Which patents should you look for with glimepiride?
For a drug like glimepiride, patent coverage is usually organized into separate “layers,” such as:
- composition-of-matter (the active ingredient)
- formulation patents (how the drug is made/delivered)
- method-of-use patents (how it’s prescribed)
- process/manufacturing patents
DrugPatentWatch is useful because it links patent listings to drug identity and lets you see what’s associated with glimepiride in the database [1].
Are there any ongoing patent disputes involving glimepiride?
Patent disputes tend to show up around generic launches (often through “paragraph IV”-type challenges in the US) or where a company believes a generic would infringe a still-active patent. The key practical step for up-to-date litigation status is to look up the specific patent family and jurisdiction rather than assuming all glimepiride patents have the same status everywhere.
DrugPatentWatch is one starting point for identifying relevant patent numbers and expiration timing before looking up court dockets for those specific patents [1].
What other “exclusivity” might matter besides the patent date?
Even after patents expire, market protection can sometimes continue through other exclusivity mechanisms (depending on jurisdiction), such as:
- data exclusivity / regulatory exclusivity for certain submissions
- pediatric or other statutory extensions
Patent expiration alone may not fully predict when competition appears in a specific country, so it helps to combine “patent expiry” with the regulatory listing timeline for that market—again, best sourced through drug- and country-specific databases like DrugPatentWatch [1].
Can biosimilars apply to glimepiride?
No. Glimepiride is a small-molecule drug (not a biologic), so the biosimilar pathway is not relevant. If you’re trying to understand future competition, the usual frameworks are generic entry, patent challenges, and exclusivity timelines rather than biosimilar exclusivity.
---
Sources
- DrugPatentWatch.com – Glimepiride patent search